ASH 2021
Oral Presentations
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors
Srinivas Tantravahi, University of Utah
143
Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK Inhibitor Therapies for Myelofibrosis
Saturday, December 11, 2021 at 1:00 p.m. ET
Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature
Paula Restrepo, Icahn School of Medicine at Mount Sinai
457
Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine
Sunday, December 12, 2021 at 12:00 p.m. ET
Enhanced p53 Activation by Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML
Yuki Nishida, Saga University
505
Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel Strategies to Overcome Resistance to BCL-2 Inhibition
Sunday, December 12, 2021 at 4:30 p.m. ET
Rationale for Selinexor Treatment in Daratumumab-Refractory Multiple Myeloma Patients Identified by Paired Ex Vivo Drug Sensitivity and RNA-Seq
Suresh Kumar Balasubramanian, Wayne State University
683
Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting Mitochondrial Survival Pathways
Monday, December 13, 2021 at 3:45 p.m. ET
Comparison of Salvage Autologous Hematopoietic Cell Transplantation with Outcomes Following Selinexor Combinations Among Double/Triple Refractory Myeloma Patients
Praneeth Sudalagunta, H Lee Moffitt Cancer Ctr
893
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Myeloma Pathogenesis and Novel Targets
Monday, December 13, 2021 at 7:15 p.m. ET
Poster Presentations
Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)
Suzanne Lentzsch, Columbia University Irving Medical Center
1651
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I
Saturday, December 11, 2021 at 5:30 – 7:30 p.m. ET
Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)
Nizar Bahlis, University of Calgary
1634
Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
Saturday, December 11, 2021 at 5:30 – 7:30 p.m. ET
Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-label, Multicenter GEM-SELIBORDARA Study Presenter: Paula Rodríguez- Otero, Clínica Universidad de Navarra
Paula Rodríguez- Otero, Clínica Universidad de Navarra
1677
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I
Saturday, December 11, 2021 at 5:30 – 7:30 p.m. ET
Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma
Darrell White, QEII Health Sciences Center, Dalhousie University
2748
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II
Sunday, December 12, 2021 at 6:00 – 8:00 p.m. ET
Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment
Muhamed Baljevic, University of Nebraska Medical Center
2751
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II
Sunday, December 12, 2021 at 6:00 – 8:00 p.m. ET
Single Cell RNA Sequencing of a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in RRMM Patients
Yael Cohen, Tel Aviv Sourasky Medical Center
2725
Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
Sunday, December 12, 2021 at 6:00 – 8:00 p.m. ET
Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA
Matthew Blunt, University of Southampton
2411
Lymphomas: Translational—Non-Genetic: Poster II
Sunday, December 12, 2021 at 6:00 – 8:00 p.m. ET
Molecular Response Patterns in Relapsed/Refractory AML Patients Treated with Selinexor and Chemotherapy
Piroska Klement, Hannover Medical School
2369
Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Sunday, December 12, 2021 at 6:00 – 8:00 p.m. ET
Updated Efficacy of Eltanexor Monotherapy in Patients with Higher Risk Hypomethylating Myelodysplastic Syndrome Primary Refractory to Hypomethylating Agents
Sangmin Lee, Weill Cornell Medical College
3676
Myelodysplastic Syndromes — Clinical and Epidemiological: Poster III
Monday, December 13, 2021 at 6:00 – 8:00 p.m. ET
Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the BOSTON Study
Sundar Jagannath, Mount Sinai School of Medicine
3793
Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III
Monday, December 13, 2021 at 6:00 – 8:00 p.m. ET
Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: SELINDA Phase Ib LYSA Study
Marie Maerevoet, Jules Bordet Institute
1411
Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I
Saturday, December 11, 2021 at 5:30 – 7:30 p.m. ET
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Seung Tae Lee, University of Maryland School of Medicine
1420
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I
Saturday, December 11, 2021, 5:30-7:30PM ET